Ray Therapeutics

“We’re at an exciting juncture in medicine where the perceived scientific boundaries in treatment across therapeutic areas continue to dissolve.” These words from Jeffrey Jones , chief medical office

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Talaris Calls It Quits In Reverse-Merge

After the year’s slow start, venture capital fundraising by drug developers has gotten a big boost in recent months, especially in May when two companies raised more than $700m between them – $300m fo